Casopitant (Oral) And ZOFRAN To Prevent Postoperative Nausea And Vomiting In Women

• Status: Completed
• Trial end date: 2006-07-01
• Target enrollment: 0
• Participant gender: Female

Summary

This study is being conducted to see if adding GW679769 (casopitant) to ZOFRAN will significantly decrease the number of patients who experience nausea and vomiting after surgery.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Casopitant; Neurokinin-1 Receptor Antagonists

Criteria

Inclusion criteria:

• History of PONV and/or motion sickness.

• Have not smoked for the last 6 months.

• Having certain types of abdominal, breast or shoulder surgeries.

Exclusion criteria:

• Pregnant or breastfeeding.

• Taking certain medications.

• Have certain pre-existing medical conditions.